Eli Lilly's biggest growth driver, tirzepatide, will continue facing scrutiny from investors and analysts. The company's oral ...

Early intervention in psoriatic arthritis (PsA) is disease-modifying, and delays in diagnosis, even by 6 months, can reduce ...

Alberto Conca, CIO at Swiss wealth manager LFG+ZEST, has been adding exposure to pharma, biotech and medtech in recent weeks, ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

On Thursday’s episode of Mad Money, host Jim Cramer turned his focus to large-cap stocks that surged by $10 or more in a single day.

Key Points President Trump has threatened to levy tariffs of up to 200% on pharmaceutical imports.Lilly's margins could be negatively affected if the company absorbs the higher costs.However, any ...

Shares of Johnson & Johnson climbed 6.8% in morning trading, enough to pace the S&P 500 index's SPX gainers. They were also headed for their biggest one-day gain and best postearnings reaction since ...

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.